Home » Stocks » Tiziana Life Sciences

Tiziana Life Sciences PLC (TLSA)

Stock Price: $3.43 USD -0.19 (-5.25%)
Updated Sep 22, 2020 1:11 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 327.84M
Revenue (ttm) n/a
Net Income (ttm) -9.32M
Shares Out 95.58M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 22, 2020
Last Price $3.43
Previous Close $3.62
Change ($) -0.19
Change (%) -5.25%
Day's Open 3.60
Day's Range 3.41 - 3.78
Day's Volume 130,205
52-Week Range 0.62 - 12.17

More Stats

Market Cap 327.84M
Enterprise Value 328.46M
Earnings Date (est) Oct 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 95.58M
Float n/a
EPS (basic) -0.14
EPS (diluted) -0.14
FCF / Share -0.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14,346
Short Ratio 0.11
Short % of Float 0.00%
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 168.74
Revenue n/a
Operating Income -9.92M
Net Income -9.32M
Free Cash Flow -6.80M
Net Cash -620,000
Net Cash / Share -0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -133.38%
ROE n/a
ROIC 217.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $3.43
Target: 11.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-9.92-9.87-10.49-9.88
Net Income-9.32-7.93-8.59-9.77
Shares Outstanding136141--
Earnings Per Share-0.14-0.12-0.18-0.22
Operating Cash Flow-6.80-4.60-7.53-6.93
Capital Expenditures----0.05
Free Cash Flow-6.80-4.60-7.53-6.97
Cash & Equivalents0.205.300.065.80
Total Debt0.82---
Net Cash / Debt-0.625.300.065.80
Book Value-5.510.52-2.284.09
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tiziana Life Sciences PLC
Country United Kingdom
Employees 8
CEO Kunwar Shailubhai

Stock Information

Ticker Symbol TLSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TLSA
IPO Date March 24, 2000


Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.